8-KEarnings & ResultsLeadership ChangesOther Events+1

DEXCOM INC 8-K Report, Financial Results (Nov 6, 2013)

Filed November 6, 2013For Securities:DXCM

Summary

DexCom, Inc. (DXCM) filed an 8-K on November 6, 2013, primarily to report its financial results for the third quarter of 2013 and to announce a new director appointment. The company's financial performance for the quarter ended September 30, 2013, was detailed in an accompanying press release furnished with the filing. This information is crucial for investors seeking to understand the company's operational and financial standing during the period. In addition to financial updates, the filing announced the election of Steve Altman to the Board of Directors, effective November 4, 2013. Mr. Altman's appointment as a Class II director, with a term expiring at the 2016 Annual Meeting, and his equity compensation package are also disclosed. This board expansion and the terms of Mr. Altman's compensation provide insight into the company's governance and its approach to attracting experienced leadership.

Key Highlights

  • 1DexCom announced its financial results for the third quarter ended September 30, 2013, via a press release.
  • 2Steve Altman was elected to the DexCom Board of Directors as a Class II director.
  • 3Mr. Altman's term as a director will expire at the 2016 Annual Meeting of stockholders.
  • 4Mr. Altman received a one-time grant of restricted stock units valued at $300,000 upon his appointment.
  • 5The restricted stock units granted to Mr. Altman vest over 36 months in three equal annual installments.
  • 6Non-employee directors receive an annual retainer of $37,500 in the form of restricted stock units, which for Mr. Altman was prorated.
  • 7All restricted stock unit grants will accelerate in full upon a change of control of DexCom.

Frequently Asked Questions

The 8-K filing references a press release (Exhibit 99.01) that contains DexCom's financial results for the third quarter of 2013. Specific figures such as revenue, earnings per share, and any year-over-year growth would be detailed within that press release.

Steve Altman was elected to the DexCom Board of Directors as a Class II director, effective November 4, 2013. He is expected to serve until the 2016 Annual Meeting of stockholders. His appointment expands the board to eight directors.

Mr. Altman received a one-time grant of restricted stock units valued at $300,000, which vest over 36 months. He will also receive an annual retainer of $37,500 in restricted stock units, prorated from his appointment date. These grants are subject to vesting schedules and acceleration upon a change of control.

This 8-K filing primarily serves to report past financial results and announce corporate actions. While the press release furnished (Exhibit 99.01) might contain forward-looking statements or guidance, this particular 8-K filing itself does not explicitly provide new financial targets or guidance.